Literature DB >> 14981195

How long is IVIg effective in multifocal motor neuropathy?

F Terenghi1, A Cappellari, A Bersano, M Carpo, S Barbieri, E Nobile-Orazio.   

Abstract

The authors treated 10 patients with multifocal motor neuropathy (MMN) responding to an initial course of IV immunoglobulin (IVIg) with periodic infusion for 5 to 12 years (mean 8.2 years). At last follow-up, only two patients had maintained the maximal improvement achieved during therapy while eight worsened despite increasing Ig dosage. This decline started after 3 to 7 years (mean 4.8 years) of therapy and correlated with a reduction of distal compound muscle action potential amplitudes (p < 0.019). The effectiveness of IVIg in MMN often declines after several years possibly associated with the development of axonal degeneration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981195     DOI: 10.1212/01.wnl.0000110185.23464.a1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 2.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 4.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

5.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 6.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 7.  The pathogenesis of multifocal motor neuropathy and an update on current management options.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Ruxandra Iancu Ferfoglia
Journal:  Ther Adv Neurol Disord       Date:  2015-05       Impact factor: 6.570

8.  Immunoglobulin (Ig) in multifocal motor neuropathy (MMN): update on evidence for Ig treatment in MMN.

Authors:  J-M Léger
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy.

Authors:  Khushali S Jhaveri; Ilana Schlam; Noa G Holtzman; Monica Peravali; Perry K Richardson; Saurabh Dahiya; Vera Malkovska; Aaron P Rapoport
Journal:  Blood Adv       Date:  2020-12-08

Review 10.  [Current use of immunoglobulins in neurology].

Authors:  S Cursiefen; M Mäurer
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.